{"id":140328,"date":"2026-10-04T16:05:49","date_gmt":"2026-10-04T16:05:49","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/140328\/"},"modified":"2026-10-04T16:05:49","modified_gmt":"2026-10-04T16:05:49","slug":"roche-says-drug-helped-patients-reduce-blood-sugar-levels-weight-in-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/140328\/","title":{"rendered":"Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial"},"content":{"rendered":"<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u e108qypx0\"><a data-type=\"company\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/ROP\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">Roche<\/a> <a color=\"var(--color-inkSubtle)\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/CH\/XSWX\/ROP\" class=\"css-1fr2kw9-ChicletStyle e1vl9ktx2\" rel=\"nofollow noopener\" target=\"_blank\">ROP -1.72%decrease; down pointing triangle<\/a> Holding said an <a data-type=\"subject\" href=\"https:\/\/www.wsj.com\/topics\/subject\/obesity\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">obesity<\/a> drug candidate met the main objectives of a midstage clinical trial by helping patients reduce their blood glucose and body weight.<\/p>\n<p data-type=\"paragraph\" data=\"[object Object]\" class=\"css-1qg6i2u e108qypx0\">The Swiss pharmaceutical company is seeking to enter the weight-loss drug market that <a data-type=\"company\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/LLY\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">Eli Lilly<\/a> <a color=\"var(--color-inkSubtle)\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/LLY\" class=\"css-1fr2kw9-ChicletStyle e1vl9ktx2\" rel=\"nofollow noopener\" target=\"_blank\">LLY -0.01%decrease; down pointing triangle<\/a> and <a data-type=\"company\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/DK\/XCSE\/NOVO.B\" target=\"_blank\" class=\"ekxajjj0 css-i0lbhy-OverridedLink\" rel=\"nofollow noopener\">Novo Nordisk<\/a> <a color=\"var(--color-inkSubtle)\" href=\"https:\/\/www.wsj.com\/market-data\/quotes\/DK\/XCSE\/NOVO.B\" class=\"css-1fr2kw9-ChicletStyle e1vl9ktx2\" rel=\"nofollow noopener\" target=\"_blank\">NOVO.B -0.24%decrease; down pointing triangle<\/a> currently dominate, and sees the latest trial results reinforcing its ambitions to rapidly develop a portfolio of medicines for people with obesity, diabetes and cardiovascular disease.<\/p>\n<p>Copyright \u00a92026 Dow Jones &amp; Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Roche ROP -1.72%decrease; down pointing triangle Holding said an obesity drug candidate met the main objectives of a&hellip;\n","protected":false},"author":2,"featured_media":140329,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[6277,23692,6901,65307,34156,4617,6274,1126,6273,2115,41203,45073,45075,216,14978,197,6275,16097,2783,1002,55694,4128,25348,67503,67500,6288,1831,67502,41201,228,5779,25362,25354,25361,25349,6263,2233,67501,41202,1813,337,10728,25356,1138,25351,338,25350,134,994,34155,25363,12081,5049,3381,41199,17,6278,6267,6279],"class_list":["post-140328","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ce-industry-news-filter","tag-cardiology","tag-cardiovascular-health","tag-cardiovascular-health-cardiology","tag-chrop","tag-community","tag-content-types","tag-corporate","tag-corporate-industrial-news","tag-development","tag-dknovo-b","tag-dragonfly-europe","tag-dragonfly-world","tag-eli-lilly","tag-endocrinology","tag-europe","tag-factiva-filters","tag-gcapi","tag-general-news","tag-health","tag-health-medicine","tag-healthcare","tag-healthcare-life-sciences","tag-hormonal-health","tag-hormonal-health-endocrinology","tag-industrial-news","tag-life-sciences","tag-linkendrnrealtime-linkedarticle-dnco20260923000848","tag-lly","tag-manufacturing","tag-medicine","tag-new-product","tag-new-product-service-testing","tag-new-products","tag-new-products-services","tag-newsplus","tag-novo-nordisk","tag-novo-nordisk-a-s-series-b","tag-novo-b-ko","tag-obesity","tag-pharmaceuticals","tag-political","tag-political-general-news","tag-products","tag-products-services","tag-research","tag-research-development","tag-roche","tag-roche-holding","tag-rop-eb","tag-service-testing","tag-services","tag-social-issues","tag-society","tag-society-community","tag-switzerland","tag-synd","tag-western-europe","tag-wsj-pro-wsj-com"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/140328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=140328"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/140328\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/140329"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=140328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=140328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=140328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}